Retlirafusp Alfa Biosimilar Fusion Protein (PD-L1) for Research

Pre-Made Retlirafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) extracellular fragment (20-136) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Retlirafusp alfa is a novel bifunctional fusion protein composed of a mAb against PD-L1 fused with the extracellular domain of TGF-b receptor II. Retlirafusp alfa target programmed cell death ligand-1 (PDL-1) and transforming growth factor-β (TGF-β) and exhibits antitumor activity.